How we present evidence
autologIX has zero device-specific clinical trials. Rather than overstate what we know, we organize every claim into three tiers so clinicians can evaluate the evidence for themselves.
Design certainties
Facts governed by membrane physics and device architecture. A 15 kDa molecular weight cutoff membrane with 5 nm pores physically cannot pass a platelet (2,000–4,000 nm) or an extracellular vesicle (30–1,000 nm). These are engineering facts, not performance claims.
Published evidence supporting the approach
Recovered plasma is processed through the ProtSmart 6 hollow-fiber ultrafiltration device (15 kDa molecular weight cutoff). The membrane removes plasma water, salts, and low-molecular-weight solutes while retaining platelets, plasma proteins, growth factors, and extracellular vesicles. No additional centrifugation is required for concentration.
autologIX projections
Performance expectations based on device design and analytical characterization data. These are labeled as projections pending formal validation.
Every field page below applies this framework. Where a headwind exists — such as the AAOS 2024 guideline for carpal tunnel syndrome — we disclose it.
ORTHOPEDICS
9 in 10 positive knee OA trials delivered >5 billion platelets per injection (Berrigan 2025)
WOUND CARE
52% wound area reduction at 6 weeks with the same ProtSmart filter platform (Mazzucco 2024)
HAIR RESTORATION
IGF-1: the only growth factor correlated with follicle proliferation — standard PRP misses it
SPORTS MEDICINE
PRP delivers significantly better long-term outcomes than corticosteroids for tendinopathies
SEXUAL WELLNESS
First placebo-controlled RCT: 69% achieved meaningful improvement versus 27% placebo
GYNECOLOGY
43-study scoping review: PRP improved symptoms for lichen sclerosus and vulvovaginal atrophy
